Healthcare
cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination
cbdMD, Inc. (NYSE American: YCBD), one of the nation's most recognized and trusted hemp-derived wellness companies, today announced the completion of a self-affirmed Generally Recognized as Safe (GRAS) determination supporting the safe consumption of up to 200 mg per day of cannabidiol (CBD), as delivered in the Company's proprietary broad spectrum hemp extract, in healthy adults, addressing one of the most common questions in the category of how much CBD is safe to consume per day.
About this update from Cbdmd, Inc.
Years of peer-reviewed safety research position cbdMD's broad spectrum CBD for a new era of evidence-based, clinically supported wellness. CHARLOTTE, N.C., July 7, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's most recognized and trusted hemp-derived wellness companies, today announced the completion of a self-affirmed Generally Recognized as Safe (GRAS) determination supporting the safe consumption of up to 200 mg per day of cannabidiol (CBD), as delivered in the Company's proprietary broad spectrum hemp extract, in healthy adults, addressing one of the most common questions in the category of how much CBD is safe to consume per day. The self-affirmed GRAS determination represents the culmination of years of scientific investment by cbdMD to establish a comprehensive body of evidence supporting the safety of its broad spectrum CBD products. Over the past several years, the Company has worked to develop a substantial dossier of safety data, including studies conducted in rodents, healthy human volunteers, and canines, designed to characterize the safety profile of its broad spectrum CBD formulations. This research has been published in the peer-reviewed scientific literature, spanning toxicology, genotoxicity, human tolerability, and companion-animal studies, a depth of published evidence that distinguishes cbdMD within the hemp-derived CBD category. This extensive body of evidence was assembled through a rigorous scientific program that evaluated multiple aspects of safety across relevant preclinical and clinical models. The resulting safety dossier forms the foundation of the Company's self-affirmed GRAS conclusion, which supports the intended use of cbdMD's broad spectrum CBD products at a daily intake of up to 200 mg for healthy adults. The determination was made by an independent panel of expert toxicologists following a review of the available scientific literature on the safety of cannabidiol. "The completion of our self-affirmed GRAS determination for the CBD contained in our proprietary broad spectrum blend marks a significant scientific and regulatory milestone for cbdMD," said Ronan Kennedy, CEO of cbdMD. "We have invested for years in building a robust portfolio of safety data because we believe consumers, healthcare professionals, and industry stakeholders deserve products supported by high-quality science. This achievement reflects our longstanding commitment to product quality, transparency, and scientific rigor." The determination lands at a pivotal moment for the category. In 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Substance Access Beneficiary Engagement Incentive, a first-of-its-kind initiative under which participating care organizations may offer eligible patients physician-guided access to non-intoxicating, third-party-tested hemp-derived CBD, and the U.S. Food and Drug Administration signaled enforcement discretion for orally administered CBD products meeting dietary-supplement standards in that context. As policymakers move to bring evidence-based CBD into mainstream care, cbdMD's published safety science reflects the standards this new era demands.